Mortality and survival patterns of people living with HIV-2
Identifieur interne : 001A41 ( Pmc/Corpus ); précédent : 001A40; suivant : 001A42Mortality and survival patterns of people living with HIV-2
Auteurs : Boris Tchounga ; Didier K. Ekouevi ; Eric Balestre ; François DabisSource :
- Current opinion in HIV and AIDS [ 1746-630X ] ; 2016.
Abstract
People living with HIV-2 infected usually initiate antiretroviral therapy (ART) at an advanced period in the course of their infection after a long asymptomatic period characterized by high CD4 cell count and thus at a relatively advanced age. In the new international context of early and universal ART initiation, the aim was to review survival patterns among HIV-2 infected patients, either on ART or not.
Very few reports were published on mortality in people living with HIV-2 during the last five years. People living with HIV-2 experience high mortality rates although lower than people living with HIV-1 before ART initiation. They seem to survive longer regardless of the conditions of ART use. Mortality is associated with late presentation, male gender, CD4 count <500 cell/μl, high plasma viral load, hemoglobin rate <8 g/dl) and body mass index < 18 Kg/m2.
People living with HIV-2 initiate ART later than HIV-1 and HIV duals, resulting in higher disease progression and mortality rate. The clinical management of HIV-2 infected patients should now include early diagnosis and treatment initiation as per international guidelines. Further research needs to explore the “what to start” question and document specific causes of death in people living with HIV-2 and enrolled in care in Africa.
Url:
DOI: 10.1097/COH.0000000000000299
PubMed: 27254747
PubMed Central: 5055442
Links to Exploration step
PMC:5055442Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mortality and survival patterns of people living with HIV-2</title><author><name sortKey="Tchounga, Boris" sort="Tchounga, Boris" uniqKey="Tchounga B" first="Boris" last="Tchounga">Boris Tchounga</name><affiliation><nlm:aff id="A1">Université de Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, Bordeaux, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2">INSERM U1219 – Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3">Programme PACCI, site de recherche ANRS, Abidjan, Côte d’Ivoire</nlm:aff></affiliation></author><author><name sortKey="Ekouevi, Didier K" sort="Ekouevi, Didier K" uniqKey="Ekouevi D" first="Didier K" last="Ekouevi">Didier K. Ekouevi</name><affiliation><nlm:aff id="A1">Université de Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, Bordeaux, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2">INSERM U1219 – Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3">Programme PACCI, site de recherche ANRS, Abidjan, Côte d’Ivoire</nlm:aff></affiliation><affiliation><nlm:aff id="A4">Université de Lomé, Département de Santé Publique, Lomé-Togo</nlm:aff></affiliation></author><author><name sortKey="Balestre, Eric" sort="Balestre, Eric" uniqKey="Balestre E" first="Eric" last="Balestre">Eric Balestre</name><affiliation><nlm:aff id="A1">Université de Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, Bordeaux, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2">INSERM U1219 – Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France</nlm:aff></affiliation></author><author><name sortKey="Dabis, Francois" sort="Dabis, Francois" uniqKey="Dabis F" first="François" last="Dabis">François Dabis</name><affiliation><nlm:aff id="A1">Université de Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, Bordeaux, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2">INSERM U1219 – Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27254747</idno><idno type="pmc">5055442</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055442</idno><idno type="RBID">PMC:5055442</idno><idno type="doi">10.1097/COH.0000000000000299</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">001A41</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001A41</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Mortality and survival patterns of people living with HIV-2</title><author><name sortKey="Tchounga, Boris" sort="Tchounga, Boris" uniqKey="Tchounga B" first="Boris" last="Tchounga">Boris Tchounga</name><affiliation><nlm:aff id="A1">Université de Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, Bordeaux, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2">INSERM U1219 – Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3">Programme PACCI, site de recherche ANRS, Abidjan, Côte d’Ivoire</nlm:aff></affiliation></author><author><name sortKey="Ekouevi, Didier K" sort="Ekouevi, Didier K" uniqKey="Ekouevi D" first="Didier K" last="Ekouevi">Didier K. Ekouevi</name><affiliation><nlm:aff id="A1">Université de Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, Bordeaux, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2">INSERM U1219 – Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3">Programme PACCI, site de recherche ANRS, Abidjan, Côte d’Ivoire</nlm:aff></affiliation><affiliation><nlm:aff id="A4">Université de Lomé, Département de Santé Publique, Lomé-Togo</nlm:aff></affiliation></author><author><name sortKey="Balestre, Eric" sort="Balestre, Eric" uniqKey="Balestre E" first="Eric" last="Balestre">Eric Balestre</name><affiliation><nlm:aff id="A1">Université de Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, Bordeaux, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2">INSERM U1219 – Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France</nlm:aff></affiliation></author><author><name sortKey="Dabis, Francois" sort="Dabis, Francois" uniqKey="Dabis F" first="François" last="Dabis">François Dabis</name><affiliation><nlm:aff id="A1">Université de Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, Bordeaux, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2">INSERM U1219 – Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France</nlm:aff></affiliation></author></analytic><series><title level="j">Current opinion in HIV and AIDS</title><idno type="ISSN">1746-630X</idno><idno type="eISSN">1746-6318</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Purpose of review</title><p id="P1">People living with HIV-2 infected usually initiate antiretroviral therapy (ART) at an advanced period in the course of their infection after a long asymptomatic period characterized by high CD4 cell count and thus at a relatively advanced age. In the new international context of early and universal ART initiation, the aim was to review survival patterns among HIV-2 infected patients, either on ART or not.</p></sec><sec id="S2"><title>Recent findings</title><p id="P2">Very few reports were published on mortality in people living with HIV-2 during the last five years. People living with HIV-2 experience high mortality rates although lower than people living with HIV-1 before ART initiation. They seem to survive longer regardless of the conditions of ART use. Mortality is associated with late presentation, male gender, CD4 count <500 cell/μl, high plasma viral load, hemoglobin rate <8 g/dl) and body mass index < 18 Kg/m<sup>2</sup>.</p></sec><sec id="S3"><title>Summary</title><p id="P3">People living with HIV-2 initiate ART later than HIV-1 and HIV duals, resulting in higher disease progression and mortality rate. The clinical management of HIV-2 infected patients should now include early diagnosis and treatment initiation as per international guidelines. Further research needs to explore the “what to start” question and document specific causes of death in people living with HIV-2 and enrolled in care in Africa.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">101264945</journal-id><journal-id journal-id-type="pubmed-jr-id">34537</journal-id><journal-id journal-id-type="nlm-ta">Curr Opin HIV AIDS</journal-id><journal-id journal-id-type="iso-abbrev">Curr Opin HIV AIDS</journal-id><journal-title-group><journal-title>Current opinion in HIV and AIDS</journal-title></journal-title-group><issn pub-type="ppub">1746-630X</issn><issn pub-type="epub">1746-6318</issn></journal-meta><article-meta><article-id pub-id-type="pmid">27254747</article-id><article-id pub-id-type="pmc">5055442</article-id><article-id pub-id-type="doi">10.1097/COH.0000000000000299</article-id><article-id pub-id-type="manuscript">NIHMS811745</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Mortality and survival patterns of people living with HIV-2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tchounga</surname><given-names>Boris</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ekouevi</surname><given-names>Didier K</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Balestre</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dabis</surname><given-names>François</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Université de Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, Bordeaux, France</aff><aff id="A2"><label>2</label>INSERM U1219 – Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France</aff><aff id="A3"><label>3</label>Programme PACCI, site de recherche ANRS, Abidjan, Côte d’Ivoire</aff><aff id="A4"><label>4</label>Université de Lomé, Département de Santé Publique, Lomé-Togo</aff><author-notes><corresp id="FN1"><bold>Corresponding author:</bold> Pr François DABIS, MD, PhD, Centre de Recherche INSERM U.1219, Institut de Santé Publique, Epidémiologie et Développement (ISPED), Université de Bordeaux, ISPED, CS61292, 33076 BORDEAUX Cedex - FRANCE, Tel: 33 (0) 5. 57.57.14.36, <email>Francois.Dabis@u-bordeaux.fr</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>30</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>9</month><year>2017</year></pub-date><volume>11</volume><issue>5</issue><fpage>537</fpage><lpage>544</lpage><pmc-comment>elocation-id from pubmed: 10.1097/COH.0000000000000299</pmc-comment>
<abstract><sec id="S1"><title>Purpose of review</title><p id="P1">People living with HIV-2 infected usually initiate antiretroviral therapy (ART) at an advanced period in the course of their infection after a long asymptomatic period characterized by high CD4 cell count and thus at a relatively advanced age. In the new international context of early and universal ART initiation, the aim was to review survival patterns among HIV-2 infected patients, either on ART or not.</p></sec><sec id="S2"><title>Recent findings</title><p id="P2">Very few reports were published on mortality in people living with HIV-2 during the last five years. People living with HIV-2 experience high mortality rates although lower than people living with HIV-1 before ART initiation. They seem to survive longer regardless of the conditions of ART use. Mortality is associated with late presentation, male gender, CD4 count <500 cell/μl, high plasma viral load, hemoglobin rate <8 g/dl) and body mass index < 18 Kg/m<sup>2</sup>.</p></sec><sec id="S3"><title>Summary</title><p id="P3">People living with HIV-2 initiate ART later than HIV-1 and HIV duals, resulting in higher disease progression and mortality rate. The clinical management of HIV-2 infected patients should now include early diagnosis and treatment initiation as per international guidelines. Further research needs to explore the “what to start” question and document specific causes of death in people living with HIV-2 and enrolled in care in Africa.</p></sec></abstract><kwd-group><kwd>HIV-2</kwd><kwd>survival</kwd><kwd>mortality</kwd><kwd>antiretroviral therapy</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A41 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001A41 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:5055442
|texte= Mortality and survival patterns of people living with HIV-2
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:27254747" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |